influenza
vaccin
usual
nonadjuv
addit
adjuv
may
improv
immunogen
permit
dosespar
critic
vaccin
suppli
event
influenza
pandem
aim
firstinman
studi
determin
effect
delta
inulin
adjuv
safeti
immunogen
reduc
dose
season
influenza
vaccin
healthi
male
femal
adult
age
year
recruit
particip
random
control
studi
compar
safeti
toler
immunogen
reduceddos
southern
hemispher
trival
inactiv
influenza
vaccin
formul
advax
tm
delta
inulin
adjuv
ltiv
adj
compar
fulldos
standard
tiv
vaccin
contain
adjuv
ltiv
adj
provid
equival
immunogen
standard
tiv
vaccin
assess
hemagglutin
inhibit
hi
assay
vaccin
strain
well
number
heterosubtyp
strain
hi
respons
sustain
month
postimmunis
group
antibodi
landscap
larg
panel
influenza
virus
show
distinct
age
effect
wherebi
subject
year
old
bimod
baselin
hi
distribut
pattern
highest
hi
titer
oldest
isol
second
hi
peak
influenza
isol
last
year
contrast
subject
year
unimod
baselin
hi
distribut
peak
recognit
isol
approxim
year
ago
reduc
dose
tiv
vaccin
contain
advax
adjuv
well
toler
safeti
issu
identifi
henc
delta
inulin
may
use
adjuv
use
season
pandem
influenza
vaccin
australia
new
zealand
clinic
trial
registri
influenza
vaccin
usual
nonadjuv
addit
adjuv
may
improv
immunogen
permit
dosespar
critic
vaccin
suppli
event
influenza
pandem
aim
firstinman
studi
determin
effect
delta
inulin
adjuv
safeti
immunogen
reduc
dose
season
influenza
vaccin
healthi
male
femal
adult
age
year
recruit
particip
random
control
studi
compar
safeti
toler
immunogen
reduceddos
southern
hemispher
trival
inactiv
influenza
vaccin
formul
advax
tm
delta
inulin
adjuv
ltiv
adj
compar
fulldos
standard
tiv
vaccin
contain
adjuv
ltiv
adj
provid
equival
immunogen
standard
tiv
vaccin
assess
hemagglutin
inhibit
hi
assay
vaccin
strain
well
number
heterosubtyp
strain
hi
respons
sustain
month
postimmunis
group
antibodi
landscap
larg
panel
influenza
virus
show
distinct
age
effect
wherebi
subject
year
old
bimod
baselin
hi
distribut
pattern
highest
hi
titer
oldest
isol
second
hi
peak
influenza
isol
last
year
contrast
subject
year
unimod
baselin
hi
distribut
peak
recognit
isol
approxim
year
ago
reduc
dose
tiv
vaccin
contain
advax
adjuv
well
toler
safeti
issu
identifi
henc
delta
inulin
may
use
adjuv
use
season
pandem
influenza
vaccin
australia
new
zealand
clinic
trial
registri
elsevi
ltd
right
reserv
despit
widespread
nation
immun
program
season
influenza
continu
caus
signific
morbid
mortal
suscept
popul
includ
chronic
diseas
elderli
restrict
routin
use
season
influenza
vaccin
develop
world
rel
high
cost
reflect
logist
produc
larg
quantiti
influenza
viru
egg
cellcultur
hypothes
adjuv
addit
permit
antigen
dosespar
therebi
cost
influenza
vaccin
make
afford
provid
support
design
lowdos
futur
pandem
influenza
vaccin
advax
novel
polysaccharid
adjuv
base
semicrystallin
particl
inulin
shown
preclin
studi
enhanc
vaccin
immunogen
protect
across
broad
rang
pathogen
includ
japanes
enceph
west
nile
viru
hiv
hepat
b
sar
coronaviru
listeria
anthrax
advax
adjuv
also
shown
benefit
influenza
provid
enhanc
vaccin
protect
ferret
high
pathogen
avian
influenza
given
influenza
vaccin
pregnant
dam
provid
enhanc
passiv
protect
pup
overcom
neonat
immun
immatur
use
vaccin
sevendayold
mous
pup
human
studi
ad
pandem
human
vaccin
trial
enhanc
seroconvers
seroprotect
rate
similarli
benefici
effect
immunogen
hepat
b
vaccin
insect
sting
allergi
desensitis
treatment
firstinman
phase
studi
undertaken
assess
safeti
toler
efficaci
advax
adjuv
includ
reduceddos
season
tiv
vaccin
studi
conduct
random
subjectand
observerblind
parallelgroup
trial
flinder
medic
centr
adelaid
australia
assess
safeti
immunogen
antigenspar
advaxadjuv
tiv
vaccin
healthi
adult
subject
age
year
studi
approv
flinder
clinic
research
ethic
committe
exclus
includ
pregnanc
immunosuppress
therapi
diabet
mellitu
immunodefici
disord
oral
corticosteroid
hiv
infect
drug
alcohol
abus
histori
vaccin
egg
allergi
prior
receipt
season
influenza
vaccin
initi
stage
studi
subject
random
receiv
either
standard
fulldos
tiv
vaccin
lg
ha
dose
tiv
antigen
lg
ha
formul
mg
advax
tm
delta
inulin
adjuv
complet
initi
studi
arm
subject
also
recruit
tiv
dose
lg
ha
advax
adjuv
arm
sign
inform
consent
randomis
venesect
baselin
serolog
singl
vaccin
dose
administ
intramuscular
inject
ml
vaccin
nondomin
deltoid
muscl
week
postimmun
blood
obtain
assess
antiinfluenza
immun
respons
solicit
local
system
reaction
collect
memori
aid
seriou
advers
event
collect
throughout
studi
period
causal
advers
event
assess
blind
investig
influenza
viru
specif
antibodi
determin
elisa
previous
describ
briefli
elisa
plate
coat
betapropiolacton
bpl
inactiv
vaccin
compon
refer
viral
antigen
kindli
suppli
collabor
influenza
refer
research
influenza
melbourn
australia
overnight
block
h
use
vv
bovin
serum
albumin
pb
serum
sampl
ad
duplic
vv
dilut
pb
h
wash
biotinyl
mous
antihuman
igg
igm
abcam
usa
ad
incub
h
follow
wash
addit
hrpconjug
streptavidin
h
plate
wash
tetramethylbenzidin
substrat
ad
min
stop
phosphor
acid
optic
densiti
od
well
read
nm
od
spectrophotomet
plate
reader
versamax
molecular
devic
analyz
use
softmax
pro
softwar
mean
od
calcul
dilut
antibodi
titer
measur
hemagglutin
inhibit
hi
assay
previous
describ
titer
express
reciproc
highest
serum
dilut
inhibit
hemagglutin
serum
assay
respons
three
vaccin
virus
also
variant
influenza
strain
virus
test
propag
embryon
hen
egg
repres
vaccin
serotyp
three
coprimari
efficaci
endpoint
seroprotect
hi
titer
seroconvers
increas
hi
titer
fold
increas
geometr
mean
hi
titer
gmt
data
analysi
perform
prism
version
graphpad
softwar
inc
ca
usa
baselin
characterist
compar
use
ttest
chisquar
anova
exact
binomi
confid
interv
report
proport
end
point
report
pvalu
twosid
adjust
multipl
test
p
consid
signific
geometr
mean
gmt
confid
interv
comput
take
expon
mean
lower
upper
limit
confid
interv
log
e
transform
titer
antibodi
landscap
construct
pre
post
vaccin
sampl
subject
standard
tiv
subject
ltiv
adj
studi
arm
order
compar
magnitud
vaccin
respons
throughout
broader
rang
antigen
space
antigen
map
methodolog
use
previous
describ
methodolog
updat
detail
support
onlin
materi
total
subject
enrol
initi
two
studi
arm
standard
tiv
ltiv
adj
complet
arm
addit
subject
subsequ
recruit
ltiv
adj
arm
baselin
characterist
studi
popul
shown
tabl
subject
median
age
year
predominantli
caucasian
rel
even
split
male
femal
signific
differ
studi
group
baselin
characterist
hi
titer
vaccin
compon
relat
strain
igm
igg
respons
immunis
assess
elisa
day
postimmun
signific
baselin
differ
igm
igg
level
three
vaccin
compon
standard
tiv
ltiv
adj
group
fig
vaccin
group
demonstr
signific
rise
igm
igg
day
postimmun
dpv
compar
baselin
level
expect
igm
peak
group
dpv
declin
dpv
contrast
igg
reach
peak
similar
pattern
igm
igg
respons
observ
vaccin
compon
howev
ltiv
adj
associ
significantli
lower
igm
dpv
nevertheless
except
influenza
b
titer
dpv
igg
level
significantli
differ
standard
tiv
ltiv
adj
arm
wherea
elisa
measur
total
quantiti
antibodi
bind
inactiv
influenza
antigen
hi
assay
measur
level
specif
function
antibodi
bind
ha
head
prevent
bind
host
sialic
acid
receptor
differ
group
baselin
mean
gmt
tabl
standard
tiv
ltiv
adj
group
robust
hi
respons
week
postimmun
would
pass
european
union
committe
medicin
product
human
use
chmp
season
influenza
vaccin
criteria
adult
year
old
requir
seroprotect
seroconvers
gmt
fold
rise
even
ltiv
adj
group
exceed
chmp
criteria
tabl
overal
signific
differ
seen
hi
titer
ltiv
adj
ltiv
adj
group
compar
standard
tiv
group
tabl
notabl
standard
tiv
ltiv
adj
ltiv
adj
group
still
pass
least
chmp
criteria
variant
b
strain
hi
assay
also
perform
blood
collect
month
postimmun
assess
antibodi
persist
group
receiv
tiv
ltiv
adj
hi
titer
three
vaccin
three
variant
strain
remain
elev
baselin
month
postimmun
fig
antibodi
landscap
recent
use
techniqu
better
characteris
full
extent
antibodi
respons
induc
influenza
infect
andor
immunis
explor
phenomena
detail
individu
antibodi
landscap
influenc
subject
age
past
exposur
influenza
infect
andor
immunis
averag
group
respons
give
robust
comparison
respons
differ
vaccin
strain
although
previous
use
compar
respons
differ
vaccin
strain
effect
adjuv
may
global
antibodi
respons
influenza
never
analyz
way
therefor
sought
compar
subset
trial
subject
age
year
less
complet
hi
antigen
map
differ
virus
oldest
date
back
first
strain
infect
human
baselin
preimmunis
hi
titer
virus
similar
two
vaccin
group
except
standard
tiv
group
slightli
higher
level
reactiv
oldest
strain
fig
support
onlin
materi
subject
analyz
age
year
mark
differ
pattern
baselin
hi
titer
seen
support
onlin
materi
would
expect
due
differ
exposur
histori
set
vaccin
recipi
older
group
show
higher
titer
oldest
strain
test
howev
titer
recent
virus
significantli
higher
year
age
categori
pattern
easili
attribut
differ
exposur
histori
notabl
subject
year
old
bimod
baselin
hi
distribut
pattern
highest
baselin
hi
titer
oldest
isol
second
hi
peak
influenza
isol
last
year
contrast
subject
year
unimod
baselin
hi
distribut
peak
recognit
isol
approxim
year
ago
support
onlin
materi
chang
week
postimmunis
hi
titer
map
compar
differ
respons
across
antigen
space
recipi
either
ltiv
adj
standard
tiv
vaccin
reach
signific
howev
trend
recipi
ltiv
adj
higher
hi
respons
across
complet
antigen
spectrum
split
age
signific
differ
respons
vaccin
group
although
smaller
size
group
subset
decreas
sensit
analysi
seriou
advers
event
sae
unexpect
advers
event
observ
studi
analysi
biochem
haematolog
safeti
test
reveal
clinic
relev
chang
baselin
studi
group
data
shown
number
solicit
system
advers
effect
significantli
differ
standard
tiv
alon
group
event
compar
ltiv
adj
group
event
tabl
nonsignific
trend
higher
rate
feverpyrexia
arthralgia
standard
tiv
group
could
reflect
higher
rna
content
henc
higher
agonist
activ
frequenc
solicit
local
reaction
compar
group
standard
tiv
ltiv
adj
extrem
well
toler
low
rate
local
reaction
local
reaction
red
swell
frequenc
less
significantli
differ
group
grade
local
reaction
report
current
studi
undertaken
assess
safeti
dosespar
capabl
advax
novel
delta
inulinbas
polysaccharid
adjuv
first
time
advax
adjuv
test
human
season
tiv
vaccin
vaccin
formul
advax
adjuv
remain
immunogen
even
reduc
even
standard
tiv
dose
whilst
hi
titer
regard
best
predictor
influenza
protect
elisa
assay
provid
opportun
explor
effect
antibodi
isotyp
interestingli
although
ltiv
adj
associ
significantli
lower
antiinfluenza
igm
level
translat
lower
igg
hi
titer
ltiv
without
adjuv
includ
studi
arm
possibl
say
whether
lower
igm
respons
might
due
lower
vaccin
dose
andor
presenc
advax
adjuv
previou
analysi
vaccin
respons
across
antigen
space
use
antibodi
landscap
reveal
larg
part
antibodi
respons
influenza
vaccin
appear
result
surprisingli
extens
recal
prior
immun
term
backboost
studi
corrobor
find
detect
vaccin
respons
reach
back
way
oldest
influenza
strain
studi
group
previous
unknown
effect
adjuv
would
phenomena
whether
would
exampl
favor
respons
novel
futur
strain
disproportion
increas
backboost
effect
respons
older
strain
find
studi
indic
neither
strongli
favor
respons
maintain
addit
adjuv
despit
reduc
antigen
dose
baselin
preimmunis
antibodi
landscap
clearli
demonstr
impact
past
influenza
exposur
individu
pattern
hi
titer
older
hi
respons
vaccin
strain
shade
gray
variant
strain
white
gmt
increas
shown
fold
chang
rel
baselin
subject
like
recognis
oldest
variant
older
individu
lower
baselin
titer
recent
strain
less
clear
howev
may
repres
decay
antibodi
titer
time
inde
sera
elderli
individu
show
littl
detect
antibodi
reactiv
strain
despit
live
four
decad
circul
fact
differ
seen
age
group
reassur
support
efficaci
ltiv
adj
may
also
influenc
lack
elderli
individu
studi
would
inform
use
antibodi
landscap
examin
effect
adjuv
vaccin
recipi
phenomena
immunesenesc
may
play
larger
role
enhanc
vaccin
immunogen
antigenspar
expens
toler
safeti
current
approv
adjuv
tiv
vaccin
contain
squalen
oil
emuls
formul
adjuv
approv
use
elderli
tiv
vaccin
contain
adjuv
extens
studi
shown
enhanc
vaccin
immunogen
elderli
young
children
whilst
adjuv
well
recognis
propens
caus
modestli
increas
inject
site
pain
muscl
ach
metaanalys
confirm
posit
safeti
profil
includ
lack
associ
vaccin
increas
risk
narcolepsi
immunis
subject
find
high
import
given
increas
narcolepsi
seen
children
immun
vaccin
pandemrix
gsk
belgium
adjuv
squalenebas
adjuv
also
contain
tocopherol
despit
welldemonstr
benefit
adjuv
vaccin
immunogen
high
level
commun
apprehens
regard
adjuv
safeti
need
acknowledg
consider
consum
educ
like
requir
success
introduc
new
adjuv
season
influenza
market
advax
made
delta
isoform
inulin
sugar
use
intraven
year
test
kidney
function
reassuringli
frequenc
system
advers
effect
significantli
differ
ltiv
adj
compar
standard
tiv
group
mechan
action
advax
adjuv
remain
intens
studi
current
evid
point
toward
noninflammatori
enhanc
antigen
present
cell
function
mean
enhanc
vaccin
action
current
studi
limit
due
phase
studi
primarili
conduct
establish
safeti
advax
adjuv
combin
season
influenza
vaccin
studi
assess
longterm
vaccin
seroprotect
requir
least
month
followup
studi
design
includ
control
group
reduc
tiv
dose
without
adjuv
howev
previou
studi
intraderm
administ
vaccin
contain
lg
ha
g
standard
dose
lg
ha
standard
dose
induc
inferior
hi
respons
b
solid
black
line
repres
degre
antibodi
reactiv
measur
postvaccin
gray
show
baselin
prevaccin
averag
group
blue
shade
show
addit
reactiv
dpv
c
comparison
hi
titer
increas
vaccin
standard
tiv
ltiv
adj
posit
along
antigen
summari
path
horizont
midpoint
black
line
indic
higher
respons
group
vaccin
ltiv
adj
midpoint
present
denot
higher
respons
group
vaccin
standard
tiv
data
calcul
averag
titer
increas
individu
pair
preand
postvaccin
titer
dark
gray
light
gray
testbas
confid
interv
ttest
weight
consid
subject
pretit
detect
rang
given
antigen
point
postpr
could
therefor
reliabl
calcul
plot
dot
along
x
axe
indic
antigen
posit
virus
use
gener
landscap
label
also
antigen
cluster
panel
c
vertic
dot
line
indic
antigen
posit
vaccin
viru
also
circl
tabl
list
system
advers
event
standard
lg
ha
vaccin
suggest
good
immunogen
seen
studi
even
tiv
advax
dose
like
effect
adjuv
larger
studi
reduc
tiv
alon
control
group
requir
exactli
quantit
advax
antigenspar
effect
anoth
limit
measur
hi
respons
perfect
predictor
influenza
protect
influenzaspecif
cell
recent
shown
human
studi
predict
influenza
protect
import
measur
effect
advax
adjuv
tcell
respons
futur
studi
firstinman
phase
studi
confirm
advax
adjuv
combin
season
influenza
vaccin
well
toler
safe
human
subject
plan
futur
studi
assess
benefit
advax
adjuv
season
influenza
vaccin
elderli
highrisk
subject
well
use
pandem
influenza
vaccin
